The Cincinnati Center for Eosinophilic Disorders has an unprecedented ability to make strides in our understanding of eosinophilic disorders. Our researchers are worldwide leaders in the field, conducting basic, translational, and clinical studies to determine the causes of eosinophilic disorders, develop better treatments, and find a cure. In addition to our investigator-initiated studies, whose results have fueled the development of novel therapeutics, our center has served as the primary site for multi-center drug trials from Glaxo-Smith Kline, Novartis and Cephalon Therapeutics.
> Read more
